Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder

Abstract

Pagoclone is a cyclopyrrolone that is believed to act as a partial agonist at the γ-aminobutyric acid (GABA) A/benzodiazepine (BDZ) receptor. In theory, such partial agonists should be anxiolytic but lack the adverse side-effects of sedation, tolerance and withdrawal associated with full GABA-A/BDZ agonists. The objective of the randomized double-blind crossover study was to assess whether pagoclone was an effective anti-panic agent and also to assess its side-effect profile. Patients recruited had a diagnosis of Panic Disorder (DSM-IV) with at least one panic attack per week. Following a 2-week screening period, patients entered a 6-week trial consisting of two 2-week treatment periods, each followed by a 1-week washout. Patients were randomly assigned to receive either pagoclone 0.1 mg t.d.s. or placebo on their first treatment period and the converse on their second. The primary measure was daily panic attack dairy. Fourteen patients completed the study, the mean number of panic attacks during screening was 5.8 ± 0.8 (SEM), this fell to 3.6 ± 0.5 during treatment with pagoclone (p = 0.05) and 4.3 ± 0.8 with placebo (p = 0.14). There was no significant difference on direct comparison of pagoclone with placebo or in any of the secondary measures (including Rickels withdrawal scale) or the adverse event profiles. The study provides preliminary evidence that pagoclone has anxiolytic properties in the absence of typical BDZ side-effects. This is consistent with its theoretical mode of action as a partial agonist at the GABAA/BDZ receptor.

Keywords

GABA pagoclone panic disorder partial agonist

Get full access to this article

View all access options for this article.

References

American Psychiatric Association (1990) Benzodiazepine dependence, toxicity and abuse (Task Force Recommendations). American Psychiatric Press Inc., Washington, DC

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC

Andersch J C , Rosenberg N K , Kullingsjo H (1991) Efficacy and safety of alprazolam, imipramine and placebo in the treatment of panic disorder. A Scandinavian multicentre study. Acta Psychiatr Scand 365 (Suppl.): 18–27

Ballenger J C , McDonald S , Noyes R , Rickels K , Sussman N , Woods S , Patin J , Singer J (1991) The first double-blind, placebo-controlled trial of a partial benzodiazepine agonists, abecarnil (ZK112-119) in generalized anxiety disorder. Psychopharmacol Bull 27(2): 171–179

Chevalier J F , Mendlewicz J , Coupez R et al. (1993) Safety and efficacy of alpidem. In Bartholini G , Carreau M , Morselli P L et al. (eds), Imidazopyridines in anxiety disorders: a novel experimental and therapeutic approach, pp. 193–199.Raven Press, New York

Chouinard G , Labonte A , Fontaine R (1983) New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 7: 669–673

Doble A , Canton, T , Dreisler S , Piot O , Boireau A , Stutzmann J M , Bardone M C , Rataud J , Roux M , Roussel G , Bourzat J D , Cotrel C , Pauchet C , Zundel J L , Blanchard J C (1993) RP 59037 and RP 60503: anxiolytic cyclopyrrolone derivatives with low sedation potential. interaction with the GABAA/benzodiazepine receptor complex and behavioural effects in the rodent. J Pharmacol Exp Therapeut 266: 1213–1226

Legris P , George Y , Boval P et al. (1993) A comparative study of alpidem verses buspirone. In Bartholini G , Garreau M , Morselli P L (eds), Imidazopyridines in anxiety disorders: a novel experimental and therapeutic approach, pp. 183–192. Raven Press, New York

Lingford-Hughes A , Uhl N , Feeney A , Wilson S , Grasby P , D'Orlando K , Gammans R , Nutt D (2000) Is pagoclone a partial agonist at the central GABA-benzodiazepine receptor: a [11C]flumazenil PET study. Abstract for the XIII CINP

10.

Mant T G K (1995) A phase 1 double blind, parallel group, placebo-controlled tolerability and pharmacokinetic study of IP-456 administered as repeated doses (3 doses/day) to healthy male volunteers (Protocol IP 456–001). Guy's Drug Research Unit Limited Report, 9 September

11.

Mant T G K (1996) A phase 1 double blind, paralle.l group, placebo-controlled tolerability and pharmacokinetic study of RP 62955 administered as a single rising oral dose (from 0.02–2 mg) to healthy male volunteers (Protocol NGB 101). Guy's Drug Research Unit Limited Report, 2 April

12.

Peturrson H , Lader M (1981) Withdrawal from long-term benzodiazepine treatment. Br Med J 283: 643–645

13.

Potokar J P , Nutt D J (1994) Anxiolytic potential of benzodiazepine receptor partial agonists. CNS Drugs 1: 305–315

14.

Rickels K , Schweizer E (1986) Benzodiazepines for the treatment of panic attacks: a new look. Psychopharmacol Bull 22: 93–99

15.

Sandford J J , Argyropoulos S , Nutt D J (2000) The psychobiology of anxiolytic drugs (Part 1): basic neurobiology. Pharmacol Therapeut 88: 197–212

16.

Truffinet P H (1995) Double-blind placebo-controlled tolerability study of RP 59037 in 12 healthy volunteers after single sequential increasing oral doses of 0.2 mg, 0.4 mg, 1 mg, 1.6 mg, 3 mg, 5 mg, and possible intermediary doses (Protocol CY1002). RPR Medical Report, 25 January